大麻二醇的非线性血蛋白结合
Mariana Babayeva1, Iva Srdanovic2
1Department of Biomedical and Pharmaceutical Sciences, Touro College of Pharmacy, 3 Times Square, New York, NY, 10036, USA. mariana.babayeva@touro.edu.
大麻素 (CBD) 的血蛋白结合在高度下是非线性的,可能会影响药物的疗效. 在CBD配方中避免酸和聚乙烯材料. 提佐化物与CBD结合没有相互作用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物新陈代谢 药物新陈代谢
- 材料科学 材料科学 材料科学
背景情况:
- 大麻 (CBD) 具有较高的血蛋白结合,影响其药理活性.
- 蛋白质结合的变化可以改变未结合的CBD度和治疗效果.
- 这项研究调查了CBD与蛋白质结合的非线性性质以及与tizoxanide的潜在相互作用.
研究的目的:
- 为了确定大麻 (CBD) 与血蛋白的结合是否依赖于度.
- 评估提佐化物改变CBD蛋白结合的可能性.
- 识别可能与CBD相互作用并影响其输送的材料.
主要方法:
- 用过技术来评估CBD在人体血中的蛋白质结合.
- 用不同的CBD度准备了样本,有或没有tizoxanide.
- 高性能液态染色学 (HPLC) 用于微分割后的分析.
主要成果:
- 大麻二醇被证明与玻璃酸盐 (9%) 和聚乙烯塑料 (15%) 结合.
- 与低度相比,高度的CBD未结合的部分大约是高度的2倍,表明非线性结合.
- 在CBD和tizoxanide之间没有观察到显著的结合相互作用,在两种情景中,未结合的分量保持在5%.
结论:
- 在较高度下,大麻素 (CBD) 的血蛋白结合是非线性的,影响药物的排泄和疗效.
- 在CBD产品的配方,包装和管理中,应避免酸盐和聚乙烯材料.
- 同时服用CBD药物和提佐胺被认为是安全的,因为没有检测到影响结合的药物相互作用.
更多相关视频
05:25Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
Published on: December 29, 2021
10:17Creating Highly Specific Chemically Induced Protein Dimerization Systems by Stepwise Phage Selection of a Combinatorial Single-Domain Antibody Library
Published on: January 14, 2020
相关概念视频
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
Drug Distribution: Plasma Protein Binding
Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
Protein-Drug Binding: Mechanism and Kinetics
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Nonlinear Pharmacokinetics: Overview
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinear Pharmacokinetics: Causes of Nonlinearity
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...
